Acquisition

Oxford Biomedica PLC
15 March 2007


                              Oxford BioMedica PLC

      Completion of acquisition of Oxxon Therapeutics and issue of shares


Oxford, UK - 15 March 2007: Further to the announcement of 12 March 2007, Oxford
BioMedica plc (LSE: OXB, 'Oxford BioMedica' or the 'Company') is pleased to
announce that the acquisition of Oxxon Therapeutics Limited ('Oxxon') (the
'Acquisition') has now completed. The consideration for the Acquisition was
satisfied by the issue of 27,551,628 new ordinary shares of 1p each in the
Company (with a further 4,219,618 such shares issued to certain Oxxon
shareholders in repayment of a loan from them to Oxxon) (together, the
'Shares'). The Shares were admitted to the Official List of the UK Listing
Authority and to trading on the London Stock Exchange with effect from 8 a.m.
today.


In conformity with the FSA's Disclosure and Transparency Rules, we notify the
market that the Company's issued share capital consists of 533,511,200 ordinary
shares of 1p each with voting rights. No shares are held in Treasury.


Therefore, the total number of voting rights in Oxford BioMedica is 533,511,200.


The above figure may be used by shareholders as the denominator for the
calculation by which they will determine if they are required to notify their
interest in, or a change of their interest in, Oxford BioMedica under the FSA's
Disclosure and Transparency Rules.


                                       -Ends-

For further information, please contact:

Oxford BioMedica plc:

Professor Alan Kingsman, Chief Executive                               Tel: [phone]

N M Rothschild & Sons Limited

Dr Lynn Drummond                                                       Tel: [phone]

City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan                  Tel: [phone]

Communications

Scientific/Trade Press Enquiries:

Gemma Price/ Holly Griffiths/ Katja Stout                              Tel: [phone]

Northbank Communications


N M Rothschild & Sons Limited, which is authorised and regulated by the
Financial Services Authority in the United Kingdom, is acting for Oxford
BioMedica and no one else in relation to the Acquisition and will not be
responsible to anyone other than Oxford BioMedica for providing the protections
afforded to clients of N M Rothschild & Sons Limited nor for providing advice in
relation to the Acquisition or any other matter referred to in this
announcement.


                      This information is provided by RNS
            The company news service from the London Stock Exchange